News
In an interview with Dr. Phil, the health secretary offered false information about vaccine oversight and revealed a lack of ...
Following massive layoffs and cuts at the FDA, Makary’s plan for the agency is yet to fully unfold. But he has hinted at what ...
As tariffs, HHS workforce cuts and the ouster of CBER Director Peter Marks threaten the “lifeblood” of the cell and gene ...
The FDA has discussed with vaccine-maker Novavax the need for an additional trial of its COVID-19 vaccine as a post-approval ...
Healthcare in the U.S. is expensive, there's no doubt about that. In fact, the Peter G. Peterson Foundation found that the ...
As Marty Makary nears the end of his first month on the job, the FDA Commissioner sat down for two interviews, offering ...
The new FDA chief reiterated his commitment to speeding up drug approval processes and run the agency by “gold standard ...
Long a lobbying powerhouse in Washington, pharma’s struggling to settle on a strategy for defending itself, according to six industry lobbyists and three company officials who spoke to POLITICO. All ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results